Please assess the completion status of the following clinical trial:

Trial Title: The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pulmonary Hypertension~* Using subcutaneous treprostinil~* Already participating as a subject in our prospective study of infusion site pain~* Has documented debilitating pain (6/10 or greater) in the study after a site change~Exclusion Criteria:~* Uncontrolled hypertension~* Recent stroke or myocardial infarction

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Qutenza patch (Type: EXPERIMENTAL): All participants actively treated with Qutenza

Based on this trial design, predict the completion outcome and termination type (if applicable).